BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li X, Gao P, Niu J. Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury. Biomed Res Int 2019;2019:8764093. [PMID: 31531370 DOI: 10.1155/2019/8764093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Shimizu Y, Sasaki T, Takeshita JI, Watanabe M, Shizu R, Hosaka T, Yoshinari K. Identification of average molecular weight (AMW) as a useful chemical descriptor to discriminate liver injury-inducing drugs. PLoS One 2021;16:e0253855. [PMID: 34170966 DOI: 10.1371/journal.pone.0253855] [Reference Citation Analysis]
2 Ferron PJ, Gicquel T, Mégarbane B, Clément B, Fromenty B. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury? Biochimie 2020;179:266-74. [PMID: 32891697 DOI: 10.1016/j.biochi.2020.08.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
3 Li X, Xu H, Gao P. Increased red cell distribution width predicts severity of drug-induced liver injury: a retrospective study. Sci Rep 2021;11:773. [PMID: 33436893 DOI: 10.1038/s41598-020-80116-4] [Reference Citation Analysis]